|Dr. Terry J. Rosen Ph.D.||Co-Founder, Chairman & CEO||341.2k||N/A||1960|
|Dr. Juan Carlos Jaen||Co-Founder, Pres & Director||751.2k||N/A||1958|
|Dr. William J. Grossman||Chief Medical Officer||677.27k||N/A||1970|
|Mr. Jason Barker||VP of Fin. and Principal Financial & Accounting Officer||N/A||N/A||1971|
|Ms. Yvonne Gehring||VP of HR & Operations||N/A||N/A||N/A|
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc. Arcus Biosciences, Inc. was founded in 2015 and is based in Hayward, California.
Arcus Biosciences, Inc.’s ISS Governance QualityScore as of December 5, 2019 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 8; Compensation: 9.